Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Venous thromboembolism in the hematologic malignancies

Venous thromboembolism in the hematologic malignancies REVIEW URRENT Venous thromboembolism in the hematologic PINION malignancies Anna Falanga, Marina Marchetti, and Laura Russo Purpose of review This review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (VTE) in patients with lymphoma, multiple myeloma or acute leukemia. Recent findings Hematologic malignancies are associated with a high risk of thrombotic complications. The incidence of these events is greatly variable and is influenced by many factors, including the type and the stage of disease, antitumor therapies, and the use of central venous device (CVD). Epidemiological data allow an estimate of the incidence of VTE in acute leukemia, lymphomas, and multiple myeloma. The effect of chemotherapy on the incidence of thrombosis is particularly evident in acute leukemia as it causes the exacerbation of the clotting/bleeding syndrome typical of this disease. The role of chemotherapy is also relevant in lymphoma, and in multiple myeloma, in which the use of immunomodulating agents, in combination with chemotherapy and steroids significantly increases the risk of VTE. Summary Thrombotic complications have a significant impact on morbidity and mortality of hematological cancer patients, therefore, in this setting, the issue of thromboprophylaxis to prevent VTE is important. However, no clear recommendation in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Oncology Wolters Kluwer Health

Venous thromboembolism in the hematologic malignancies

Russo, Laura
Current Opinion in Oncology , Volume 24 (6) – Nov 1, 2012
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/venous-thromboembolism-in-the-hematologic-malignancies-ifyib6o0l0

References (71)

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1040-8746
eISSN
1531-703X
DOI
10.1097/CCO.0b013e3283592331
pmid
23014188
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Venous thromboembolism in the hematologic PINION malignancies Anna Falanga, Marina Marchetti, and Laura Russo Purpose of review This review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (VTE) in patients with lymphoma, multiple myeloma or acute leukemia. Recent findings Hematologic malignancies are associated with a high risk of thrombotic complications. The incidence of these events is greatly variable and is influenced by many factors, including the type and the stage of disease, antitumor therapies, and the use of central venous device (CVD). Epidemiological data allow an estimate of the incidence of VTE in acute leukemia, lymphomas, and multiple myeloma. The effect of chemotherapy on the incidence of thrombosis is particularly evident in acute leukemia as it causes the exacerbation of the clotting/bleeding syndrome typical of this disease. The role of chemotherapy is also relevant in lymphoma, and in multiple myeloma, in which the use of immunomodulating agents, in combination with chemotherapy and steroids significantly increases the risk of VTE. Summary Thrombotic complications have a significant impact on morbidity and mortality of hematological cancer patients, therefore, in this setting, the issue of thromboprophylaxis to prevent VTE is important. However, no clear recommendation in

Journal

Current Opinion in Oncology – Wolters Kluwer Health

Published: Nov 1, 2012

There are no references for this article.